NCT05893862View on ClinicalTrials.gov

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Schizophrenia
Interventions
DRUG

MK-8189

Oral Tablet

DRUG

Moxifloxacin

Oral Tablet

DRUG

Placebo

Oral Tablet

Trial Locations (4)

33009

Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale

91206

California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0003), Glendale

92868

NRC Research Institute ( Site 0004), Orange

08053

Hassman Research Institute Marlton Site ( Site 0001), Marlton

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT05893862 - A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019) | Biotech Hunter | Biotech Hunter